Science
Stefanie Perna Nacar: Botensilimab/Balstilimab Shows Major Pathologic Responses in Colon Cancer
Stefanie Perna Nacar/LinkedIn

Stefanie Perna Nacar: Botensilimab/Balstilimab Shows Major Pathologic Responses in Colon Cancer

Stefanie Perna Nacar, Chief Communications & Government Relations Officer at Agenus, shared on LinkedIn:

“Based on these results and other from UNICORN the team is working hard to open our global Phase 3 ROBBIN study investigating BOT/BAL in the neoadjuvant setting for stage II/III MSS colon cancer.”

Title: Botensilimab/Balstilimab Elicits Major Pathologic Responses in Colon Cancer

Authors: Tim Cortese, Russ Conroy

Read The Full Article

You may also be interested in: France Expands Reimbursed Compassionate Access for Botensilimab/Balstilimab to Ovarian Cancer and Soft-Tissue Sarcomas
Stefanie Perna Nacar: Botensilimab/Balstilimab Shows Major Pathologic Responses in Colon Cancer

Balstilimab BOT/BAL botensilimab cancer cancer immunotherapy clinical trials Colon cancer immunotherapy major pathologic response MSS colon cancer neoadjuvant therapy neoadjuvant treatment OncoDaily Oncology Pathologic Response ROBBIN Study Russ Conroy stage II colon cancer Stage III Colon Cancer Stefanie Perna Nacar Tim Cortese UNICORN